Hudson Bay Capital Management
NTLA icon

Hudson Bay Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Hudson Bay Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Hold
60,000
– – ﹤0.01% 915
2026
Q1 		$769K Sell
60,000
-255,000
-81% -$3.25M ﹤0.01% 922
2025
Q4 		$2.83M Buy
315,000
+85,000
+37% +$1.17M 0.01% 639
2025
Q3 		$3.97M Sell
230,000
-235,000
-51% -$2.89M 0.01% 610
2025
Q2 		$4.36M Sell
465,000
-100,000
-18% -$821K 0.01% 576
2025
Q1 		$4.02M Buy
565,000
+52,700
+10% +$532K 0.01% 659
2024
Q4 		$5.97M Buy
512,300
+177,300
+53% +$2.77M 0.02% 468
2024
Q3 		$6.88M Buy
335,000
+60,000
+22% +$1.38M 0.03% 357
2024
Q2 		$6.15M Buy
275,000
+27,700
+11% +$660K 0.03% 341
2024
Q1 		$6.8M Buy
247,300
+9,800
+4% +$272K 0.04% 239
2023
Q4 		$7.24M Buy
237,500
+52,300
+28% +$1.5M 0.05% 242
2023
Q3 		$5.86M Buy
185,200
+25,200
+16% +$978K 0.05% 252
2023
Q2 		$6.52M Sell
160,000
-40,000
-20% -$1.62M 0.05% 259
2023
Q1 		$7.45M Sell
200,000
-8,100
-4% -$318K 0.06% 222
2022
Q4 		$7.26M Buy
208,100
+193,100
+1,287% +$9.18M 0.07% 240
2022
Q3 		$839K Sell
15,000
-55,300
-79% -$3.43M 0.01% 861
2022
Q2 		$3.64M Buy
70,300
+5,900
+9% +$300K 0.03% 570
2022
Q1 		$4.68M Buy
64,400
+34,400
+115% +$2.91M 0.06% 402
2021
Q4 		$3.55M Buy
30,000
+12,500
+71% +$1.57M 0.04% 491
2021
Q3 		$2.35M Buy
+17,500
New +$2.65M 0.03% 592

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Hudson Bay Capital Management's NTLA Position: Q2 2026 in Review

Hudson Bay Capital Management held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 60,000 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #915.

Hudson Bay Capital Management first reported a position in NTLA in Q3 2021 and has held it in 20 quarters since. The position peaked at $7.45M in Q1 2023. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Hudson Bay Capital Management held 60,000 shares of Intellia Therapeutics worth $1.02M as of Q2 2026.
  • Hudson Bay Capital Management left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #915 holding.
  • Hudson Bay Capital Management first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Hudson Bay Capital Management's Intellia Therapeutics position peaked at $7.45M in Q1 2023.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.